Amakem preclinical data

In rabbits, a single topical dose of 0.031-0.625% AMA0076 led to significant dose-dependent reductions in intraocular pressure (IOP) from baseline of 3.9-7 mmHg at 30 minutes and 4.6-7.5 mmHg at >=120 minutes vs. the vehicle-treated control eye (p<0.05). Additionally AMA0076 led to lower ocular hyperemia vs. Y-39983, a rho kinase inhibitor from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508, Osaka, Japan) that is in Phase II testing for glaucoma. ...